Italy Pulmonary Arterial Hypertension Market Size & Outlook

The pulmonary arterial hypertension market in Italy is expected to reach a projected revenue of US$ 472.5 million by 2030. A compound annual growth rate of 5.3% is expected of Italy pulmonary arterial hypertension market from 2025 to 2030.
Revenue, 2024 (US$M)
$349.7
Forecast, 2030 (US$M)
$472.5
CAGR, 2025 - 2030
5.3%
Report Coverage
Italy

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Italy pulmonary arterial hypertension market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Italy pulmonary arterial hypertension market highlights

  • The Italy pulmonary arterial hypertension market generated a revenue of USD 349.7 million in 2024 and is expected to reach USD 472.5 million by 2030.
  • The Italy market is expected to grow at a CAGR of 5.3% from 2025 to 2030.
  • In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2024.
  • SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.


Pulmonary arterial hypertension market data book summary

Market revenue in 2024USD 349.7 million
Market revenue in 2030USD 472.5 million
Growth rate5.3% (CAGR from 2025 to 2030)
Largest segmentProstacyclin and prostacyclin analogs
Fastest growing segmentSGC Stimulators
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationEndothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
Key market players worldwideUnited Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd


Other key industry trends

  • In terms of revenue, Italy accounted for 4.4% of the global pulmonary arterial hypertension market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
  • France is the fastest growing regional market in Europe and is projected to reach USD 510.5 million by 2030.

Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.9% in 2024. Horizon Databook has segmented the Italy pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.


The PAH market in Italy is projected to grow at a moderate rate over the coming years. As per the European Association of Hospital Pharmacy from January1, 2012 to August 31, 2017, an average of 4.83 patients in central Italy were treated with Volibris, Tracleer, Opsumit, Adcirca or Revatio causing higher economic burden on Italy. It was recorded that the prevalence of pulmonary arterial hypertension reported is high compared to Scotland and France.

Moreover, to reduce the economic burden of treatment, centralized procurement at the regional level was incorporated to lower the financial burden. Italy had the largest elderly population in 2019 within the EU. Its growing geriatric population is likely to promote market growth. Key initiatives by market players are expected to further boost the market.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Pulmonary Arterial Hypertension Market Companies

Name Profile # Employees HQ Website
Sandoz Group AG ADR View profile - - -
GlaxoSmithKline View profile 10001+ London, England, United Kingdom, Europe http://www.gsk.com
United Therapeutics Corp View profile 1168 1000 Spring Street, Silver Spring, MD, United States, 20910 https://www.unither.com
Viatris Inc View profile 38000 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 https://www.viatris.com
Gilead Sciences Inc View profile 18000 333 Lakeside Drive, Foster, CA, United States, 94404 https://www.gilead.com
Sun Pharmaceutical Industries View profile 10001+ Mumbai, Maharashtra, India, Asia http://www.sunpharma.com
Bayer AG View profile 99723 Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 https://www.bayer.com
Lupin View profile 10001+ Mumbai, Maharashtra, India, Asia https://www.lupin.com
Teva Pharmaceutical Industries Ltd View profile 37851 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 https://www.tevapharm.com
Johnson & Johnson View profile 134400 One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 https://www.jnj.com

Italy pulmonary arterial hypertension market size, by route of administration, 2018-2030 (US$M)

Italy Pulmonary Arterial Hypertension Market Outlook Share, 2024 & 2030 (US$M)

Italy pulmonary arterial hypertension market size, by route of administration, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online